ABSTRACT
Determination the complex of new prognostic risk factors will optimize and improve treatment and survival of patients with primary Hodgkin's Lymphoma.
Subject(s)
Biomarkers, Tumor/metabolism , Epstein-Barr Virus Infections/diagnosis , Hodgkin Disease/diagnosis , Ki-67 Antigen/metabolism , Viral Matrix Proteins/metabolism , Disease-Free Survival , Epstein-Barr Virus Infections/mortality , Epstein-Barr Virus Infections/pathology , Epstein-Barr Virus Infections/virology , Hodgkin Disease/mortality , Hodgkin Disease/pathology , Hodgkin Disease/virology , Humans , Neoplasm Staging , Prognosis , Risk FactorsABSTRACT
Management of non-Hodgkin's lymphomas (NHL) has been significantly changed during last 40 years from radiotherapy to modern polychemotherapy with application of monoclonal antibodies. A ten year experience of the treatment of patients with B-cell NHL with rituximab application was accumulated in National Cancer Institute. The group of patients with NHL, who were treated in oncohematology department in the period from 2001 to 2010, was chosen for study of the efficacy of the treatment with rituximab. The immediate and distant results of the treatment were evaluated in this group of patients. The usage of the polychemotherapy with rituximab was highly efficient in the treatment of primary and relapsed patients with NHL. This group shows high rate of the immediate and distant results of treatment.
Subject(s)
Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antigens, CD20/immunology , Antineoplastic Agents/therapeutic use , B-Lymphocytes/immunology , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/immunology , Secondary Prevention , Adult , Aged , Antibodies, Monoclonal, Murine-Derived/administration & dosage , Antigens, CD20/metabolism , Antineoplastic Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , B-Lymphocytes/cytology , Biopsy , Disease-Free Survival , Drug Administration Schedule , Female , Humans , Longitudinal Studies , Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Rituximab , T-Lymphocytes/cytology , T-Lymphocytes/immunology , Treatment Outcome , UkraineABSTRACT
The analysis of the specifics of the flow of Non-Hodgkin's lymphomas in elderly patients is presented. Comparative analysis of the treatment efficacy and toxicity with schemes CHOP and CNOP in patients is presented.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Non-Hodgkin/drug therapy , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Female , Humans , Male , Middle Aged , Mitoxantrone/administration & dosage , Mitoxantrone/adverse effects , Prednisolone/administration & dosage , Prednisolone/adverse effects , Prednisone/administration & dosage , Prednisone/adverse effects , Vincristine/administration & dosage , Vincristine/adverse effectsABSTRACT
Achievements of world practice about development and prophilaxis of tromboembolic events (VTE) in cancer patients. Particular attention is paid to prevention of VTE in patients with multiply myeloma who receive chemotherapy with Thalidomide.
Subject(s)
Fibrinolytic Agents/administration & dosage , Multiple Myeloma/drug therapy , Thalidomide/adverse effects , Thrombosis/drug therapy , Age Factors , Aspirin/administration & dosage , Aspirin/therapeutic use , Clinical Trials as Topic , Drug Combinations , Enoxaparin/administration & dosage , Enoxaparin/therapeutic use , Fibrinolytic Agents/therapeutic use , Humans , Multiple Myeloma/complications , Multiple Myeloma/physiopathology , Risk Factors , Severity of Illness Index , Thalidomide/administration & dosage , Thalidomide/therapeutic use , Thrombosis/complications , Thrombosis/physiopathology , Warfarin/administration & dosage , Warfarin/therapeutic useABSTRACT
The treatment of patients with refractory forms of Hodgkin's lymphomas in combination with chemo-radiotherapy is priority. Nevertheless, chemotherapy has to include multicomponent schemes and radiation therapy should be an addition and consolidative method to chemotherapy.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hodgkin Disease/drug therapy , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Female , Hodgkin Disease/epidemiology , Hodgkin Disease/pathology , Hodgkin Disease/radiotherapy , Humans , Male , Neoplasm Invasiveness , Neoplasm Staging , Prognosis , Radiotherapy, Adjuvant , Remission Induction , Risk Factors , Young AdultABSTRACT
The results of treatment of patients with multiple myeloma with thalidomide and complications of this treatment are presented. Monotherapy with thalidomide and its combinations with corticosteroids and cytostatics is an effective as first line treatment and as a treatment of patients with refractory disease. The most common side effect is toxic neuropathy. Other complications are less common and are easily controlled with medications.
Subject(s)
Antineoplastic Agents/therapeutic use , Multiple Myeloma/drug therapy , Thalidomide/therapeutic use , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Female , Humans , Male , Middle Aged , Neurotoxicity Syndromes/etiology , Polyneuropathies/chemically induced , Thalidomide/administration & dosage , Thalidomide/adverse effects , Treatment OutcomeABSTRACT
Number of patients with lymphomas in Ukraine increases annual. The increase of morbidity during 2007-2008 years is 4.3-8.1%. The rate of effectiveness of the treatment and patient's survival in Ukraine is lower then the world rate. Overview of main issues of the lymphoma's diagnosis and treatment in Ukraine is presented in this article.
Subject(s)
Lymphoma/diagnosis , Lymphoma/therapy , Humans , Lymphoma/epidemiology , Practice Guidelines as Topic , Treatment Outcome , Ukraine/epidemiologyABSTRACT
AIM: To determine clinical significance of PRAME gene expression in multiple myeloma (MM) and feasibility of its use as a marker of residual tumor clone. MATERIAL AND METHODS: 35 MM patients, of them 15 were newly diagnosed and 20 had resistance to previous therapy. PRAME was made if the patients received programmed therapy with high-dose chemotherapy (VD) and autologous transplantation of peripheral cell stem cells. 12 PRAME-positive patients were examined on the day +100, 5 patients--a year later. Monoclonal paraprotein was detected by electrophoresis and radial immunodiffusion of blood serum. Bone marrow affection was assessed at roentgenography and/or MRI. PRAME gene expression in bone marrow biopsy was measured by reverse transcription and PCR amplification. RESULTS: Activation of expression of PRAME gene in MM was found in 68.57% patients. It was higher in patients with MM duration more than 1 year and if they were treated before (85%) than in new cases (46.67%). Expression of PRAME tended to associate with activity of LDP of blood serum. After the above chemotherapy and autotransplantation transcript PRAME did not disappear in 8 of 12 cases. One year after the treatment, of 5 PRAME-positive patients 2 died, 1 had recurrence, 2 are in a compete clinicohematological remission. CONCLUSION: Frequent activation of transcription of the gene PRAME in MM, its assay can be used for monitoring of the disease course, assessment of remission completeness, detection of tumor cell contamination of preparations of autologous stem cells of peripheral blood.
Subject(s)
Antigens, Neoplasm/genetics , Biomarkers, Tumor/genetics , Gene Expression/genetics , Multiple Myeloma/genetics , Adult , Aged , Bone Marrow Cells/metabolism , Female , Humans , Male , Middle Aged , Multiple Myeloma/metabolism , Multiple Myeloma/therapy , Prognosis , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
Clinical-and-hematological characteristics are presented of B-cell chronic lymphoid leukosis in those persons who took part in the elimination of the effects of the Chornobyl accident in the remote period. Results are highlighted of treatment of 16 patients with making use of different chemical drug preparations. Employment of fludarabin and cyclophosphan combined in treatment of the medical condition in question has been shown to promote long-term complete and partial remissions in a major proportion of patients, which effect was not achievable with standard means of remediation. A side effect of fludarabin was leukocytopenia that in the presence of changed immunity threatened the patients with development and exacerbation of infections complications. Use of manax and erbisol moderated the immunosuppressive and toxic action of fludarabin, due to which fact infectious complications and drug-induced hepatitis have came to be less common, the patients' quality of life gotten better.
